JOP20210072A1 - ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليه - Google Patents
ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليهInfo
- Publication number
- JOP20210072A1 JOP20210072A1 JOP/2021/0072A JOP20210072A JOP20210072A1 JO P20210072 A1 JOP20210072 A1 JO P20210072A1 JO P20210072 A JOP20210072 A JO P20210072A JO P20210072 A1 JOP20210072 A1 JO P20210072A1
- Authority
- JO
- Jordan
- Prior art keywords
- same
- preparing
- pharmaceutical compositions
- compositions containing
- bcl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
يتعلق الاختراع الحالي بملح جديد وصور بلورية ذات صلة لمركب (A) حيث يكون الملح عبارة عن ملح سلفات الهيدروجين، والذي يتميز بنمط حيود أشعة سينية في المسحوق خاص به، طريقة تحضيره وتركيبات صيدلية تحتوي عليه. (A)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306430 | 2018-10-31 | ||
| PCT/EP2019/079621 WO2020089281A1 (en) | 2018-10-31 | 2019-10-30 | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210072A1 true JOP20210072A1 (ar) | 2023-01-30 |
Family
ID=64270773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0072A JOP20210072A1 (ar) | 2018-10-31 | 2019-10-30 | ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليه |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US20210355108A1 (ar) |
| EP (1) | EP3873894B1 (ar) |
| JP (1) | JP2022506137A (ar) |
| KR (1) | KR20210092750A (ar) |
| CN (1) | CN112969693A (ar) |
| AR (1) | AR116921A1 (ar) |
| AU (1) | AU2019370926A1 (ar) |
| BR (1) | BR112021007194A2 (ar) |
| CA (1) | CA3117559C (ar) |
| CL (1) | CL2021000947A1 (ar) |
| CO (1) | CO2021005077A2 (ar) |
| CR (1) | CR20210211A (ar) |
| CY (1) | CY1126057T1 (ar) |
| DK (1) | DK3873894T3 (ar) |
| DO (1) | DOP2021000074A (ar) |
| EA (1) | EA202191143A1 (ar) |
| ES (1) | ES2943511T3 (ar) |
| FI (1) | FI3873894T3 (ar) |
| GE (1) | GEP20237494B (ar) |
| HR (1) | HRP20230563T1 (ar) |
| HU (1) | HUE062000T2 (ar) |
| IL (1) | IL282565A (ar) |
| JO (1) | JOP20210072A1 (ar) |
| LT (1) | LT3873894T (ar) |
| MA (1) | MA54063B1 (ar) |
| MX (1) | MX2021004934A (ar) |
| NI (1) | NI202100025A (ar) |
| PE (1) | PE20211503A1 (ar) |
| PH (1) | PH12021550790A1 (ar) |
| PL (1) | PL3873894T3 (ar) |
| PT (1) | PT3873894T (ar) |
| RS (1) | RS64236B1 (ar) |
| SG (1) | SG11202103594XA (ar) |
| SI (1) | SI3873894T1 (ar) |
| TW (1) | TWI791916B (ar) |
| WO (1) | WO2020089281A1 (ar) |
| ZA (1) | ZA202102783B (ar) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022023514A1 (en) | 2020-07-31 | 2022-02-03 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof |
| WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
| JP2024511422A (ja) | 2021-03-24 | 2024-03-13 | レ ラボラトワール セルヴィエ | ５－｛５－クロロ－２－［（３ｓ）－３－［（モルホリン－４－イル）メチル］－３，４－ジヒドロイソキノリン－２（１ｈ）－カルボニル］フェニル｝－１，２－ジメチル－１ｈ－ピロール－３－カルボン酸誘導体を合成するための新規な製造方法及び医薬化合物を製造するためのその適用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| EP1846359A4 (en) * | 2005-01-06 | 2010-03-31 | Cj Cheiljedang Corp | INORGANIC ACID SALTS OF SIBUTRAMINE |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| CN101962387B (zh) * | 2010-09-13 | 2013-01-30 | 成都雅途生物技术有限公司 | 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法 |
| CN103664753B (zh) * | 2012-09-04 | 2017-04-26 | 上海迪赛诺化学制药有限公司 | 制备阿扎那韦硫酸氢盐a型结晶的方法 |
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI792406B (zh) * | 2015-04-15 | 2023-02-11 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途 |
-
2019
- 2019-10-30 PL PL19800947.4T patent/PL3873894T3/pl unknown
- 2019-10-30 RS RS20230347A patent/RS64236B1/sr unknown
- 2019-10-30 DK DK19800947.4T patent/DK3873894T3/da active
- 2019-10-30 CN CN201980071289.7A patent/CN112969693A/zh active Pending
- 2019-10-30 ES ES19800947T patent/ES2943511T3/es active Active
- 2019-10-30 PT PT198009474T patent/PT3873894T/pt unknown
- 2019-10-30 AU AU2019370926A patent/AU2019370926A1/en active Pending
- 2019-10-30 PE PE2021000597A patent/PE20211503A1/es unknown
- 2019-10-30 FI FIEP19800947.4T patent/FI3873894T3/fi active
- 2019-10-30 GE GEAP201915620A patent/GEP20237494B/en unknown
- 2019-10-30 EP EP19800947.4A patent/EP3873894B1/en active Active
- 2019-10-30 EA EA202191143A patent/EA202191143A1/ru unknown
- 2019-10-30 MA MA54063A patent/MA54063B1/fr unknown
- 2019-10-30 HU HUE19800947A patent/HUE062000T2/hu unknown
- 2019-10-30 LT LTEPPCT/EP2019/079621T patent/LT3873894T/lt unknown
- 2019-10-30 BR BR112021007194-6A patent/BR112021007194A2/pt unknown
- 2019-10-30 SI SI201930557T patent/SI3873894T1/sl unknown
- 2019-10-30 SG SG11202103594XA patent/SG11202103594XA/en unknown
- 2019-10-30 JP JP2021523309A patent/JP2022506137A/ja active Pending
- 2019-10-30 US US17/286,936 patent/US20210355108A1/en active Pending
- 2019-10-30 HR HRP20230563TT patent/HRP20230563T1/hr unknown
- 2019-10-30 MX MX2021004934A patent/MX2021004934A/es unknown
- 2019-10-30 JO JOP/2021/0072A patent/JOP20210072A1/ar unknown
- 2019-10-30 KR KR1020217015833A patent/KR20210092750A/ko unknown
- 2019-10-30 CR CR20210211A patent/CR20210211A/es unknown
- 2019-10-30 WO PCT/EP2019/079621 patent/WO2020089281A1/en active Application Filing
- 2019-10-30 AR ARP190103143A patent/AR116921A1/es unknown
- 2019-10-30 CA CA3117559A patent/CA3117559C/en active Active
- 2019-10-30 TW TW108139360A patent/TWI791916B/zh active
-
2021
- 2021-04-09 NI NI202100025A patent/NI202100025A/es unknown
- 2021-04-09 PH PH12021550790A patent/PH12021550790A1/en unknown
- 2021-04-16 CL CL2021000947A patent/CL2021000947A1/es unknown
- 2021-04-21 CO CONC2021/0005077A patent/CO2021005077A2/es unknown
- 2021-04-21 DO DO2021000074A patent/DOP2021000074A/es unknown
- 2021-04-22 IL IL282565A patent/IL282565A/en unknown
- 2021-04-26 ZA ZA2021/02783A patent/ZA202102783B/en unknown
-
2023
- 2023-05-18 CY CY20231100236T patent/CY1126057T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550790A1 (en) | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| JO3178B1 (ar) | النموذج السادس البلوري الجديد من مركب الاغوميلاتين وطريقة تحضيره وتحضير المركبات الصيدلانية المحتوية عليه | |
| GEP20094576B (en) | New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| GEP20094577B (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| UA83720C2 (ru) | Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит | |
| PH12018501644A1 (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MX2021002382A (es) | Sales y formas cristalinas de modulador alosterico positivo gabaa. | |
| MX2021000348A (es) | 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. | |
| UA89905C2 (ru) | α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ | |
| GEP20237490B (en) | Polymorphs | |
| MY176877A (en) | Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical compositions containing it | |
| MX2021006702A (es) | Nuevas formas cristalinas de un inhibidor de mcl-1, un proceso para su preparacion y composiciones farmaceuticas que las contienen. | |
| MX2022006984A (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina. | |
| EP4289844A3 (en) | A process for making palbociclib | |
| MY138209A (en) | New (y) crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it. | |
| MY142738A (en) | Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt | |
| TNSN05076A1 (en) | New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it | |
| TNSN05077A1 (en) | New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it | |
| TNSN05078A1 (en) | New beta crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it |